BACKGROUND: This study aims to report glycolipid changes after sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) in the setting of a prospective randomized clinical trial. METHODS:One hundred patients were randomly assigned to RYGB (n = 45) and SG (n = 55). Fasting glucose, insulin, glycated hemoglobin (HbA1c%), triglycerides, and serum cholesterol (total, HDL, and LDL) were evaluated at inclusion and after 1, 3, 6, and 12 months. The index for homeostasis model assessment of insulin resistance (HOMA-IR) and β cell function (HOMA-B) were assessed. RESULTS:Mean postoperative 1-, 3-, 6-, and 12-month excess weight loss was 25.39, 43.47, 63.75, and 80.38 % after RYGB and 25.25, 51.32, 64.67, and 82.97 % after SG, respectively. Mean fasting glucose and fasting serum insulin were similarly and statistically significantly reduced in both RYGB and SG. Mean HOMA-IR improved in both groups, particularly in case of high preoperative values, and mean HOMA-B improved at 1 year after RYGB. HbA1c% dropped from 5.66 % (SD = 0.61) to 5.57 % (SD = 0.32) after RYGB and from 5.64 % (SD = 0.43) to 5.44 % (SD = 0.43) after SG. Total cholesterol was significantly higher at 1 month (p = 0.04), 3 months (p = 0.03), and 1 year (p = 0.005) after SG as compared to RYGB. LDL cholesterol decreased significantly after RYGB at 1 month (p = 0.03), 3 months (p = 0.0001), and 1 year (p = 0.0004) as compared to SG. HDL cholesterol was increased at 1 year in the RYGB group but not in the SG group. Triglycerides decreased similarly in both groups. CONCLUSIONS: Short-term glycemic control was comparable after SG and RYGB. An improved lipid profile was noted after RYGB in patients with abnormal preoperative values.
RCT Entities:
BACKGROUND: This study aims to report glycolipid changes after sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) in the setting of a prospective randomized clinical trial. METHODS: One hundred patients were randomly assigned to RYGB (n = 45) and SG (n = 55). Fasting glucose, insulin, glycated hemoglobin (HbA1c%), triglycerides, and serum cholesterol (total, HDL, and LDL) were evaluated at inclusion and after 1, 3, 6, and 12 months. The index for homeostasis model assessment of insulin resistance (HOMA-IR) and β cell function (HOMA-B) were assessed. RESULTS: Mean postoperative 1-, 3-, 6-, and 12-month excess weight loss was 25.39, 43.47, 63.75, and 80.38 % after RYGB and 25.25, 51.32, 64.67, and 82.97 % after SG, respectively. Mean fasting glucose and fasting serum insulin were similarly and statistically significantly reduced in both RYGB and SG. Mean HOMA-IR improved in both groups, particularly in case of high preoperative values, and mean HOMA-B improved at 1 year after RYGB. HbA1c% dropped from 5.66 % (SD = 0.61) to 5.57 % (SD = 0.32) after RYGB and from 5.64 % (SD = 0.43) to 5.44 % (SD = 0.43) after SG. Total cholesterol was significantly higher at 1 month (p = 0.04), 3 months (p = 0.03), and 1 year (p = 0.005) after SG as compared to RYGB. LDL cholesterol decreased significantly after RYGB at 1 month (p = 0.03), 3 months (p = 0.0001), and 1 year (p = 0.0004) as compared to SG. HDL cholesterol was increased at 1 year in the RYGB group but not in the SG group. Triglycerides decreased similarly in both groups. CONCLUSIONS: Short-term glycemic control was comparable after SG and RYGB. An improved lipid profile was noted after RYGB in patients with abnormal preoperative values.
Authors: Mark A Attiah; Casey H Halpern; Usha Balmuri; Piergiuseppe Vinai; Shivan Mehta; Gordon H Baltuch; Noel N Williams; Thomas A Wadden; Sherman C Stein Journal: Ann Surg Date: 2012-08 Impact factor: 12.969
Authors: S Camastra; A Gastaldelli; A Mari; S Bonuccelli; G Scartabelli; S Frascerra; S Baldi; M Nannipieri; E Rebelos; M Anselmino; E Muscelli; E Ferrannini Journal: Diabetologia Date: 2011-05-26 Impact factor: 10.122
Authors: Jun Zhang; Kathryn L Kelley; Stephanie M Marshall; Matthew A Davis; Martha D Wilson; Janet K Sawyer; Robert V Farese; J Mark Brown; Lawrence L Rudel Journal: J Lipid Res Date: 2012-03-29 Impact factor: 5.922
Authors: Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal Journal: JAMA Date: 2006-04-05 Impact factor: 56.272
Authors: Melissa A Reed; Walter J Pories; William Chapman; John Pender; Rita Bowden; Hisham Barakat; Timothy P Gavin; Tom Green; Ed Tapscott; Donghai Zheng; Nigel Shankley; Lynn Yieh; David Polidori; Steven P Piccoli; Leona Brenner-Gati; G Lynis Dohm Journal: J Clin Endocrinol Metab Date: 2011-05-18 Impact factor: 5.958
Authors: David Benaiges; Antonio Más-Lorenzo; Albert Goday; José M Ramon; Juan J Chillarón; Juan Pedro-Botet; Juana A Flores-Le Roux Journal: World J Gastroenterol Date: 2015-11-07 Impact factor: 5.742
Authors: Filipe M Cunha; Joana Oliveira; John Preto; Ana Saavedra; Maria M Costa; Daniela Magalhães; Eva Lau; Rita Bettencourt-Silva; Paula Freitas; Ana Varela; Davide Carvalho Journal: Obes Surg Date: 2016-05 Impact factor: 4.129